Edition:
India

Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

859.80INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
Rs869.70
52-wk Low
Rs790.10

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: --
Market Cap(Mil.): Rs352,211.59
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 13.33 16.92
EPS (TTM): -19.13 -- --
ROI: -- -7.43 -5.76
ROE: -- -6.99 -5.08

UPDATE 1-India's Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

* Mohali was one of the plants Sun gained through Ranbaxy deal

14 Mar 2017

Mylan agreed to pay $96.5 million in Provigil antitrust class action

Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

07 Feb 2017

UPDATE 1-Mylan agreed to pay $96.5 mln in Provigil antitrust class action

Feb 6 Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

07 Feb 2017

Mylan agreed to pay $96.5 mln in Provigil antitrust class action

Feb 6 Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

06 Feb 2017

Earnings vs. Estimates